Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HARMONi-3
2023-504989-37-00Phase 3Withdrawn
- Sponsor
- Summit Therapeutics
- Start
- Jan 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 11
01
Overview
Phase 3, randomised trial of ivonescimab in Pulmonary squamous cell carcinoma (2 arms), sponsored by Summit Therapeutics. Primary endpoint: Overall survival. Planned start Jan 2024; status: withdrawn.
02
Drugs
ivonescimab
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on 2023-504989-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504989-37-00.